Clinical Trial Update: Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effects of rifampicin, a pregnane X receptor agonist, on glucose tolerance and other metabolic parameters; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Rifampicin

Snippet

Sponsor: University of Oulu | Conditions: Glucose Tolerance | Phase 4 | Status: COMPLETED